Fengxia Du
Impact in
-
- Cancer Genomics and Diagnostics
-
- Epigenetics and DNA Methylation
- Pluripotent Stem Cells Research
- CRISPR and Genetic Engineering
- Cancer-related gene regulation
- RNA modifications and cancer
- Renal and related cancers
- Bioactive Natural Diterpenoids Research
Papers in
-
- Epigenetics and DNA Methylation 4
- DNA Repair Mechanisms 2
- Pluripotent Stem Cells Research 2
- Ubiquitin and proteasome pathways 1
-
- COVID-19 Clinical Research Studies 2
- Co-authors
- Yingli Sun (9 shared papers)Caiyun Yang (7 shared papers)Minjie Zhang (6 shared papers)Jicheng Liu (1 shared paper)Huiyu Xu (1 shared paper)Zhiwei Chen (1 shared paper)Xiaohua Li (3 shared papers)Hongkui Deng (1 shared paper)
- Journals
- Biochemical and Biophysical Research Communications (3 papers)Frontiers in Pharmacology (1 paper)Cell Research (1 paper)Annals of Human Genetics (1 paper)Epigenomics (1 paper)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Fengxia Du
27 papers receiving 337 citations
Peers
Comparison fields: 5 of 72
- Cancer Research 54
- Molecular Biology 219
- Molecular Medicine 8
- Pharmacology 11
- Pulmonary and Respiratory Medicine 36
Countries citing papers authored by Fengxia Du
This map shows the geographic impact of Fengxia Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengxia Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengxia Du more than expected).
Fields of papers citing papers by Fengxia Du
This network shows the impact of papers produced by Fengxia Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengxia Du. The network helps show where Fengxia Du may publish in the future.
Co-authors
The 25 scholars most cited alongside Fengxia Du, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 59 | |
| 2 | 2012 | 30 | |
| 3 | 2023 | 29 | |
| 4 | 2014 | 28 | |
| 5 | 2018 | 25 | |
| 6 | 2018 | 22 | |
| 7 | 2019 | 18 | |
| 8 | 2019 | 18 | |
| 9 | 2015 | 17 | |
| 10 | 2022 | 15 | |
| 11 | 2017 | 14 | |
| 12 | 2020 | 11 | |
| 13 | 2025 | 9 | |
| 14 | 2014 | 8 | |
| 15 | 2014 | 8 | |
| 16 | 2023 | 5 | |
| 17 | 2022 | 4 | |
| 18 | The radioprotective agent WR1065 protects cells from radiation damage by regulating the activity of the Tip60 acetyltransferase. | 2011 | 4 |
| 19 | 2019 | 3 | |
| 20 | 2022 | 3 |
About Fengxia Du
Fengxia Du is a scholar working on Molecular Biology, Infectious Diseases, Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 30 papers that have together received 341 indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (4 papers), DNA Repair Mechanisms (2 papers), Pluripotent Stem Cells Research (2 papers), Cancer-related Molecular Pathways (2 papers), Pharmacological Effects of Natural Compounds (2 papers), Prostate Cancer Treatment and Research (2 papers), COVID-19 Clinical Research Studies (2 papers) and Ubiquitin and proteasome pathways (1 paper). The work is most often cited by research in Cancer Research (54 citations), Molecular Biology (219 citations), Molecular Medicine (8 citations), Pharmacology (11 citations) and Pulmonary and Respiratory Medicine (36 citations). Fengxia Du has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Yingli Sun, Caiyun Yang, Minjie Zhang, Jicheng Liu, Huiyu Xu, Zhiwei Chen, Xiaohua Li, Hongkui Deng, Chen Wu and Sida Shao. Their work appears in journals such as Biochemical and Biophysical Research Communications, Frontiers in Pharmacology, Cell Research, Annals of Human Genetics and Epigenomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.